
Progyny (PGNY) Stock Forecast & Price Target
Progyny (PGNY) Analyst Ratings
Bulls say
Progyny is poised for growth with California Senate Bill 729, expansion into new markets, and a focus on customer retention and profitability through efficient use of technology. Despite potential risks, the company remains optimistic and confident in their strong start to the year and expects to continue executing efficiently. With a strong competitive advantage and a target of 1M new members by 2027, Progyny's focus on fertility, family building, and women's health benefits solutions make it well-positioned for success in the expanding market.
Bears say
Progyny is a strong standalone fertility benefits management companies in the US, with a competitive edge due to its deep integration into clinical workflows driving a ~93% attachment rate. However, the lack of diversification in its revenue streams and potential competition from unbundled solutions may pose challenges for future growth. The company's strong focus on clinical outcomes and differentiated provider network provides a favorable positioning, but investors should closely monitor its client retention and competition risks.
This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.
Progyny (PGNY) Analyst Forecast & Price Prediction
Start investing in Progyny (PGNY)
Order type
Buy in
Order amount
Est. shares
0 shares